#ACC22 – Estudo randomizado | Ácido tranexâmico reduz o risco de sangramento em pacientes submetidos a cirurgia não cardíaca.

Tranexamic Acid in Patients Undergoing Noncardiac Surgery – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentários:

POISE-3: Tranexamic Acid Reduces Severe Bleeding Risk in Patients Undergoing Noncardiac Surgery – American College of Cardiology

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery – TCTMD

Comentários no Twitter

HOT OFF THE PRESS:POISE-3 Tranexamic Acid
Incidence of composite bleeding outcome significantly lower with tranexamic acid vs placebo; between-group difference in composite CV outcome was small, but noninferiority of tranexamic acid was not established.https://t.co/FyuBliD0Mr

— Steven Cohn, MD (@preopconsult) April 2, 2022

Among patients undergoing noncardiac surgery, the incidence of the composite bleeding outcome was significantly lower with tranexamic acid than with placebo. #ACC22 https://t.co/cYIQhE7YCD pic.twitter.com/l0QKgpEqnG

— NEJM (@NEJM) April 2, 2022

POISE-3 trial results showed a single dose of tranexamic acid before & after surgery significantly ⬇️ severe bleeding risk in pts undergoing noncardiac surgery compared w/ placebo. Findings could have global 🌏 impact, researchers said. https://t.co/LratgyadtE #ACC22 #cvSurg pic.twitter.com/HXlcp6bb0M

— American College of Cardiology (@ACCinTouch) April 2, 2022